Spermatogenic Failure 52 (SPGF52) Cell Models for Research

Spermatogenic Failure 52 (SPGF52) is a rare genetic disorder characterized by male infertility due to defective spermatogenesis. The exact prevalence is unknown, but it is estimated to affect a small fraction of infertile men. According to the World Health Organization (WHO), infertility affects approximately 15% of couples worldwide, with male factors contributing to about 50% of cases. SPGF52 is caused by mutations in the TEX14 gene, which is essential for intercellular bridges during spermatogenesis. The condition is inherited in an autosomal recessive manner. There is no known impact on overall survival, but it significantly affects quality of life and reproductive health. Diagnosis is typically based on semen analysis and genetic testing. Currently, there is no specific treatment, and assisted reproductive technologies may be the only option for affected individuals.

SPGF52 provides a valuable model for studying the molecular mechanisms of spermatogenesis and male infertility. The TEX14 gene is a key player in the formation of stable intercellular bridges, which are crucial for germ cell development. Understanding the function of TEX14 and the consequences of its mutations can lead to insights into other reproductive disorders and potential therapeutic targets. Public datasets, such as those from the Genotype-Tissue Expression (GTEx) project, provide expression data for TEX14 in various tissues, including the testis. Open questions include the precise role of TEX14 in different stages of spermatogenesis and the potential for gene therapy approaches.

SPGF52 is not a cancer, but a genetic disorder affecting spermatogenesis. The primary pathway involved is the formation and maintenance of intercellular bridges between spermatids. These bridges are essential for the sharing of cytoplasmic components and the synchronization of development. The TEX14 protein is a component of the germ cell intercellular bridge, and its absence leads to the failure of spermatogenesis. The pathway involves:

1. TEX14 localization to the intercellular bridge.

2. Recruitment of other proteins to form a stable bridge.

3. Maintenance of the bridge during spermatid differentiation.

4. Disruption of this process leads to spermatogenic arrest and infertility.

Data from ClinVar and the Human Gene Mutation Database (HGMD) indicate that mutations in TEX14 are the primary cause of SPGF52. The frequency of specific mutations is low due to the rarity of the disorder.

The main deregulated network is the intercellular bridge complex, which involves TEX14 and other proteins such as CEP55, RAB6A, and myosin. Disruption of this complex leads to:

• • Impaired cytoplasmic sharing between spermatids.
• • Asynchronous development of germ cells.
• • Apoptosis of spermatids.

Additionally, TEX14 may interact with the PI3K/AKT pathway, as it has been shown to affect cell survival. However, the exact signaling cascades are not fully elucidated.

Organoids derived from testicular tissue are emerging as more physiologically relevant models for studying spermatogenesis. They can recapitulate the niche environment and allow for long-term culture. However, they are technically challenging to establish and maintain.

• • TEX14 knockout mouse model: This model exhibits spermatogenic arrest and infertility, closely mimicking the human condition. It is valuable for studying the molecular mechanisms and testing potential therapies.
• • Conditional knockout models: These allow tissue-specific deletion of TEX14, enabling the study of its role in different cell types.
• • Patient-derived xenografts (PDX) are not applicable for this non-cancerous condition.

CRISPR-based gene editing has been used to create isogenic cell lines with specific TEX14 mutations. For example, a TEX14 knockout cell line can be generated in a spermatogonial cell line to study the loss-of-function effects. Similarly, knock-in cell lines with specific patient mutations (e.g., p.R123W) can be created to study the impact of missense variants. These gene-edited cell models are commercially available and sequence-verified, ensuring reproducibility and reliability. They are essential for functional genomics, drug screening, and understanding the molecular basis of SPGF52.

Gene-edited cell lines with TEX14 knockout or specific mutations are used to validate the function of TEX14 in spermatogenesis. For example, knockout cell lines can be used to assess the impact on intercellular bridge formation and cell viability. Knock-in lines with pathogenic mutations can be used to study the molecular consequences of specific variants. These models are also used in CRISPR screens to identify genetic modifiers that may rescue the phenotype.

Isogenic cell line pairs (wild-type vs. TEX14 knockout) can be used in high-throughput screening to identify compounds that restore spermatogenesis or protect germ cells. For instance, a screen for small molecules that promote intercellular bridge formation could be performed. Additionally, resistance to chemotherapeutic agents that affect spermatogenesis can be studied using these models.

CRISPR synthetic lethality screens can identify genes that are essential in TEX14-deficient cells but not in wild-type cells. These genes could serve as potential therapeutic targets for male infertility. Additionally, transcriptomic and proteomic profiling of gene-edited cells can reveal biomarkers for spermatogenic failure.